A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in obese men with uncontrolled type 2 diabetes (T2DM) suffering from hypogonadism with a subsequent 108 week open label phase to investigate long term effects on lipid distribution and cardiometabolic parameters in all participating men.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509819-87-00

Enrollment

Registered

2024-03-18

Start date

2019-07-18

Completion date

Unknown

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypogonadism, obesity, overweight, prediabetes, T2DM

Brief summary

• Change in liver fat content measured by magnetic resonance spectroscopy (MRS) from baseline to week 52

Interventions

DRUGNebido 1000 mg/4 ml Injektionslösung

DRUGPlacebo to Nebido

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• Change in liver fat content measured by magnetic resonance spectroscopy (MRS) from baseline to week 52	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026